The elderly account for the majority of medical spending in many countries, raising concerns about potentially unnecessary spending, especially during the final months of life. Using a well-defined ...

Patients not only have to fight their diseases but also must deal with the pain – the more severe the condition, the more painful the injections. Recently, new doors have opened to relieve patients of ...

Heart attack, or myocardial infarction, is one of the leading causes of death worldwide. Although modern surgical techniques, diagnostics and medications have greatly improved early survival from ...

Researchers from the Germans Trias i Pujol research institute (IGTP) have conducted a preclinical study on the effects of the drug empagliflozin, alone or in combination with sacubitril/valsartan, in ...

Myocardial ischemia, also called cardiac ischemia, is a condition characterized by reduced blood flow to the heart. A common cause is plaque buildup in the coronary arteries. Myocardial ischemia may ...

Empagliflozin stabilizes kidney function and reduces heart failure risk post-myocardial infarction, with eGFR remaining stable over 24 months. The EMPACT-MI trial confirmed empagliflozin's safety when ...

DelveInsight's, “Myocardial Infarction Pipeline Insight 2025” report provides comprehensive insights about 30+ companies and 40+ pipeline drugs in Myocardial Infarction pipeline landscape. It covers ...

Members of the editorial and news staff of Us Weekly were not involved with the creation of this content. All contributor content is reviewed by Us Weekly staff. In the landscape of global medicine, ...